drugset / Trial / NCT04662528
Safety and Efficacy of MAT9001(Omega-3-pentaenoic Acid) in Subjects With Triglycerides ≥500 mg/dL and <2000 mg/dL
RandomizedParallel-groupQuadruple-blindTreatment
Summary
To determine the efficacy of MAT9001 compared to placebo in lowering fasting triglyceride levels in subjects with very high fasting triglyceride levels ≥ 500 and \< 2000 mg/dL.
Timeline
- Start
- 2021-06
- Primary completion
- 2022-08
- Completion
- 2022-10
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | OMEGA-3-PENTAENOIC ACIDS | Small molecule | 4 g | — |
Indications
No indication recorded.